Mycophenolate mofetil for the treatment of Henoch-Schönlein purpura nephritis; current knowledge and new concepts

Azar Nickavar; Mahnaz Sadeghian

doi:10.15171/jnp.2017.17

J Nephropathol. 2017;6(3): 103-104.
doi: 10.15171/jnp.2017.17

PMID: 28975086
PMCID: PMC5607967
Scopus ID: 85019874039

Abstract View: 9492

PDF Download: 5283

Editorial

Mycophenolate mofetil for the treatment of Henoch-Schönlein purpura nephritis; current knowledge and new concepts

Azar Nickavar ¹^*, Mahnaz Sadeghian ²

¹ Department of Pediatric Nephrology, Iran University of Medical Sciences, Tehran, Iran
² Department of Pediatric Gastroenterology, Iran University of Medical Sciences, Tehran, Iran

*Corresponding Author: *Corresponding author: Azar Nickavar, Department of pediatric nephrology, Iran University of Medical Sciences, Tehran, Iran, , Email: anickavar@yahoo.com

Keywords: Henoch-Schönlein purpura,, Mycophenolate mofetil, Henoch-Schönlein purpura nephritis, Vasculitis

Implication for health policy/practice/research/medical education:

Renal involvement is the main predictive factor of long-term outcome in children with Henoch-Schönlein purpura (HSP) . Different immunosuppressive medications have been introduced for the treatment of severe HSP nephritis to prevent subsequent renal impairment. Therapeutic effect of mycophenolate mofetil and its implication have been discussed in this editorial article.

Please cite this paper as: Nickavar A, Sadeghian M. Mycophenolate mofetil for the treatment of Henoch-Schönlein purpura nephritis; current knowledge and new concepts. 2017;6(3):103-104. DOI: 10.15171/jnp.2017.17.